CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 58 enrolled
Drug / intervention
Placebo oral vial +1 moredrug
Likely dose
Choline Bitartrate 1.2 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06200883
NCT06200883Phase 4Completed
CompareCT.gov

Effects of a Nutraceutic Compound on Cognitive Impairment in Frailty Patients

Federico II University·interventional·Posted Jan 11, 2024·Updated Jan 11, 2024

In Brief

A Phase 4 clinical trial evaluating Placebo oral vial and Choline Bitartrate for Mild Cognitive Impairment. Completed, enrolled 58 participants across 1 site.

Detailed Summary

The study is designed to evaluate the effects of choline bitartrate on cognitive impairment in frailty patients. The study will analyze the impact of 4 weeks treatment randomized with a nutraceutical compound in a double-blind randomized placebo controlled trial. The investigators will also assess cognitive frailty.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment
CountriesItaly
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedJan 11, 2024
Enrollment StartSep 1, 2022
Primary CompletionSep 1, 2023
Study CompletionNov 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 2.5 years ago

Interventions

Placebo oral vialdrug

In the Placebo group the participants take vehicle (1 vial per os every 24 hours) for 4 weeks

Choline Bitartratedrug

In the CEREBRAIN group the participants take CEREBRAIN (1 vial per os of 1.2 g every 24 hours) for 4 weeks